May. 6 at 9:33 PM
Another reason why someone will acquire
$VKTX
$PFE tried to launch an oral version but discontinued it due to safety concerns.
With its new Subquantatious drug, it is struggling to achieve efficacy above 12% over 28 weeks, and is starting 10+ phase III trials, although the injections are weekly to monthly, which is an advantage for PF-08653944.
The extreme Phase III studies show how desperately big players want a piece of this market. It's growing, and it might be one of the biggest markets for pharma.
I am going to post my GLP-1 market analysis on Substack tomorrow. Follow me so you don't miss it.